RT Journal Article
SR Electronic
T1 Seroprevalence of Anti-SARS-CoV-2 Antibodies in a Cohort of New York City Metro Blood Donors using Multiple SARS-CoV-2 Serological Assays: Implications for Controlling the Epidemic and “Reopening”
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.11.06.20220087
DO 10.1101/2020.11.06.20220087
A1 Jin, Daniel K.
A1 Nesbitt, Daniel. J.
A1 Yang, Jenny
A1 Chen, Haidee
A1 Horowitz, Julie
A1 Jones, Marcus
A1 Vandergaast, Rianna
A1 Carey, Timothy
A1 Reiter, Samantha
A1 Russell, Stephen J
A1 Kyratsous, Christos
A1 Hooper, Andrea
A1 Hamilton, Jennifer
A1 Ferreira, Manuel
A1 Deng, Sarah
A1 Straus, Donna
A1 Baras, Aris
A1 Hillyer, Christopher D.
A1 Luchsinger, Larry L.
YR 2020
UL http://medrxiv.org/content/early/2020/11/07/2020.11.06.20220087.abstract
AB Projections of the stage of the Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) pandemic and local, regional and national public health policies designed to limit the spread of the epidemic as well as “reopen” cities and states, are best informed by serum neutralizing antibody titers measured by reproducible, high throughput, and statically credible antibody (Ab) assays. To date, a myriad of Ab tests, both available and authorized for emergency use by the FDA, has led to confusion rather than insight per se. The present study reports the results of a rapid, point-in-time 1,000-person cohort study using serial blood donors in the New York City metropolitan area (NYC) using multiple serological tests, including enzyme-linked immunosorbent assays (ELISAs) and high throughput serological assays (HTSAs). These were then tested and associated with assays for neutralizing Ab (NAb). Of the 1,000 NYC blood donor samples in late June and early July 2020, 12.1% and 10.9% were seropositive using the Ortho Total Ig and the Abbott IgG HTSA assays, respectively. These serological assays correlated with neutralization activity specific to SARS-CoV-2. The data reported herein suggest that seroconversion in this population occurred in approximately 1 in 8 blood donors from the beginning of the pandemic in NYC (considered March 1, 2020). These findings deviate with an earlier seroprevalence study in NYC showing 13.7% positivity. Collectively however, these data demonstrate that a low number of individuals have serologic evidence of infection during this “first wave” and suggest that the notion of “herd immunity” at rates of ∼60% or higher are not near. Furthermore, the data presented herein show that the nature of the Ab-based immunity is not invariably associated with the development of NAb. While the blood donor population may not mimic precisely the NYC population as a whole, rapid assessment of seroprevalence in this cohort and serial reassessment could aid public health decision making.Competing Interest StatementThe authors have declared no competing interest.Funding StatementFunding for this project was provided by the New York Blood Center, the Rockefeller University and Regeneron Pharmaceuticals, Inc.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Approval for donation and collection of blood from donors was attained by written consent. All donors were over 16 years of age. Ethical oversight of seroprevalence donation protocols was obtained from the institutional review board of the New York Blood Center.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll raw data will be made available upon request to the corresponding author.